IVD China last week Thermo Fisher Scientific and RealBio, Dirui and TechVital, DIAN Diagnostics, ADICON, BioChain
Published: 03 Jun 2026
Author: Towards Healthcare
RealBio and Thermo Fisher Scientific signed a strategic agreement on comprehensive quality control solutions for in vitro diagnostics. This partnership aims to combine Thermo Fisher’s global standards and technical depth with RealBio’s strengths in local translation, regulatory support, and IVD raw material development.
The shift from traditional supply relationships toward a model of shared resources and value co-creation in the IVD quality infrastructure space. These two companies seek to streamline the path from R&D to industrialization for domestic manufacturers.
According to Towards Healthcare, the China central lab market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 506.89 million in 2026 to approximately USD 1287.16 million by 2035, representing a compound annual growth rate (CAGR) of 10.91% from 2026 to 2035. Growth is driven by a focus on personalized treatments, biomarker analysis, and targeted therapies, which has made advanced testing, such as Next-Generation Sequencing (NGS), a necessity in modern trials. With regulatory frameworks, expedited drug approval processes, and heavy investments from both the government and private sectors, pharmaceutical and biologics development across the country.
About Thermo Fisher Scientific
Thermo Fisher Scientific is a dominant force in China's central laboratory and life sciences sector, operating primarily through its wholly-owned subsidiary, Thermo Fisher Scientific Co.Ltd The company commands a vast footprint spanning analytical instruments, bioprocessing, and clinical trial services. The company targets emerging markets to bolster growth and localized manufacturing capabilities to satisfy growing life science demands.
About ADICON
Adicon is capitalized to benefit from the country's rising diagnostic demand and a relatively low ICL penetration. The company operates internationally accredited laboratories, achieving high global standards that allow it to serve complex pharmaceutical research and clinical trials.
The company provides routine, specialized, and central laboratory testing services to hospitals, health check centers, biopharmaceutical clients, and contract research organizations (CROs).
By aligning global quality systems with China’s IVD innovation and manufacturing ecosystem, the two companies seek to streamline the path from R&D to industrialization for domestic manufacturers.
The collaboration marks ADICON’s shift from internal AI efficiency tools to standardized, industry-level AI services from single-point applications to an ecosystem approach for intelligent diagnostics across clinical testing, quality control, and service delivery.
A recent report by Towards Healthcare highlights that the China central lab market is witnessing growth driven by the prevalence of chronic diseases and cancer in China, which continues to necessitate advanced, biomarker-driven, and genomic clinical studies, which rely heavily on central lab infrastructure.